Dow Jones 12321.83 +5.29 6:59 am PST, November 21, 2006 NASDAQ 2453.25 +0.53 For info, visit access.smallcapnetwork.com S & P 500 1402.29 +1.79 Change your subscription status here Russell 2000 789.82 -0.80 VOLUME 06: ISSUE 93 Potential Opportunity in a Novel Cancer Treatment It's always fun to present a piece of good news about one of our profiled companies. But, when we have to decide which of two pieces of good news to start with, well...let's just say we love taking on the challenge. We think either of today's tidbits could leave investors with a very positive opinion of Multicell Technologies (OTCBB: MCET), but the combination of both items just may end up taking you all the way to a 'Wow!' status. Take a look and see if you're just as impressed as we were with the kind of cutting edge biotech work Multicell is doing in the war against cancer and MS. Better yet, take a look and see if you see the same kind of money-making potential we see in the opportunity.  To set the stage for just how big of a deal this is, we've got two questions to whet your appetite. First, were you aware there's no drug on the market specifically designed to fight Multiple Sclerosis (MS) related fatigue?  The second question is, were you aware some scientific estimates cite viruses as the root cause of about 15% of cancers? The nature of virally-induced cancers may also mean the best means for fighting them isn't necessarily the traditional methods (chemotherapy, radiation, etc.). Instead, the more effective form of treatment may be a whole new approach.  We're guessing you already know where we're going with this...Multicell has fired another shot in each of these wars. In one of the battles - the MS fatigue one - there may be an end in sight. The other - the war on virally-induced cancer - is still young. But, we think this company may also be able to reward investors over time with a novel cancer treatment. As always though, we feel the biggest portion of any potential reward for investors could possibly be dished out in advance of any final victory.    A Double Shot of News Multicell published two press releases over the last two days. The first one from Monday is the announcement about the next stage in the evolution of MCT-125. That's the drug treatment in development to treat Multiple Sclerosis fatigue. Multicell has completed an early Phase II clinical trial for MCT-125, during which significant efficacy in reducing chronic fatigue in MS patients was demonstrated. On December 1st, the next step in getting the treatment to the market is planned to be taken. On that day, Multicell is scheduled to meet with the United Kingdom's healthcare regulators to propose a plan to enter into Phase IIb trials....an important step needed to make sure Phase III testing is as conclusive and efficient as possible.  The other news released today (press release is below) is the announcement of what appears to be an incredibly effective method of treatment for virally-induced cancers, at least in the early stages of research and development. Normally, a cancer caused by a virus also results in so much damage to the patient's own immune system, the immune system is rendered ineffective. In other words, it's not so much the cancer or tumor being tough to beat - the cancer just goes unchallenged. Multicell has countered with MCT-465. This treatment is intended to induce a patient's own immune system (the 'ideal' treatment for most illnesses) to beat the cancer on its own. Here's what we think is the 'wow' part....in early lab testing, the treatment appears to have prevented morbidity and mortality in 60 percent of the samples.  Better still, MCT-465 isn't just effective in fighting cancer and tumors. It's also tested well as a treatment for influenza and other viral conditions, according to Multicell. So, we can't wait to see how things progress on this front.  So what? Here's what....the annual global cancer market is estimated to be worth $10 to $20 billion. The annual global MS market is estimated to be worth $2 to $3 billion. Folks, even a smidgen of those amounts would still be a windfall for Multicell. And here's the kicker - we don't see Multicell just throwing their hat in the ring in order to capture a little market share. In our opinion, Multicell is really working on drug therapies that are (1) cutting-edge, and (2) effective. We think that mentality is a huge corporate advantage. After all, when it comes to lives potentially being saved, we feel a company that appears to provide the best shot of doing so could also enjoy enormous demand for their drug therapies. And, we think investors could be the direct beneficiaries of that kind of demand. Got your attention?    A Second Chance? We don't think you see too many second chances in the market - or in life, for that matter. However, that's what we think we've got when we see MCET's current chart.  After our initial profile was issued on September 28th, the stock surged from 26 cents to close at 43 cents on the 29th. Although we were thrilled for those folks who were already in a position - or able to get into one at a low trading level - we were also wondering if the big move would cause other speculators to think the majority of any gain was already realized. Our opinion was/is that the opportunity is bigger than 43 cents, even if it's going to take longer than a day to get to what we feel is this stock's full potential.  Fortunately, if you liked the opportunity then, then we think you may like the second chance for an entry at the same low trading level you had less than two months ago. The stock has fallen back to 26 cents again, as of Monday. The interesting part about the past two months is, as we see it, a string of announcements like the ones we detailed above actually makes the investment an even better opportunity.  Now don't misunderstand....we're not saying we think this thing's going from 26 cents to 26 bucks today. We are saying, however, we see a lot of things going well for this company - and not just today's double play. As far as we're concerned, Multicell just has too many promising drug projects in the works to ignore (54 current or pending patents at last count). Like we said back in early October, we feel this company's big library of biopharma technology could give them many ways to win in the near and distant future. The two announcements we mentioned here are just a couple more reasons our opinion of this opportunity is being reiterated. From our point of view, MCET's potential reward deserves serious attention from aggressive investors today.    Multicell Technologies Demonstrates Drug Candidate's Powerful Tumor-Destroying Capabilities for Virally Induced Cancers such as Cervical Cancer  Company's Patented Toll-like Receptor Agonist and Ig-Peptide Therapeutic Eradicates Cancer in Preclinical Animal Model  Tuesday, November 21, 9:25 am ET -- MultiCell Technologies, Inc. (OTCBB: MCET), developing first-in-class drugs based on advanced immune system modulation and other proprietary technologies, today announced that co-administration of MCT-465, a Toll-like Receptor (TLR) agonist, with the Company's patented antigen presenting immunoglobulin therapeutic resulted in the control of primary tumor growth, induced the immune system to completely destroy the tumors, and ultimately prevented morbidity and mortality in 60 percent of treated animals.  MultiCell's unique technology platforms, designed to treat disease by modulation of the human immune system, may have valuable application as a treatment for deadly diseases such as cervical cancer and other cancers that are caused by viruses.  The method involves the loading of an antigen presenting cell with at least one tumor associated T-cell epitope attached to an immunoglobulin backbone to form an Ig-peptide molecule ("IgNP") followed by administration the IgNP in conjunction with MCT-465, a dsRNA TLR agonist adjuvant therapeutic.  "We believe these experimental results represent a potentially valuable breakthrough in cancer treatment. Several cancers, such as cervical cancer, are induced by viruses, and are able to overpower the immune system and spread throughout the body," said Dr. Stephen Chang, Chief Executive Officer of Multicell Technologies. "We demonstrated conclusively that co-administration of MCT-465 with a virus specific epitope grafted to our patented antigen presenting immunoglobulin therapeutic ("IgNP") completely destroyed tumors and prevented mortality."  MultiCell is an innovator in the science of modulating the human immune system with unique platform technologies, focusing on the development of breakthrough drugs to treat serious autoimmune diseases, including multiple sclerosis and type-1 diabetes, as well as influenza. Currently, the market for therapies that address these diseases is estimated at $8 billion worldwide. The new therapeutic combination further expands the Company's potential therapeutic development targets to include cancer.  "Our work in this area was recently published in the Journal of Immunology, and we have filed several patents covering the technology," noted Dr. Chang.  "The most exciting aspect of our work is we administered MCT-465 and IgNP after the tumor had grown to a very large size in the animal, and observed complete destruction of the tumor by the animal's immune system. We were able to overcome cancer's ability to hide from detection by the immune system. We believe that the implications for this work are far-reaching and could someday help treat the millions of patients suffering from various cancers," said Dr. Chang.  About MultiCell Technologies, Inc.  MultiCell Technologies, Inc. is an integrated biopharmaceutical company committed to the development of breakthrough therapeutics based on a portfolio of therapeutic candidates and patented drug development technology. MultiCell's drug development program is focused on modulation of the immune system.  MultiCell's therapeutic pipeline includes drug candidates some of which are in various advanced stages of human clinical trials. These therapies include:  MCT-125 for the treatment of chronic fatigue in MS patients. MCT-125 completed a Phase II clinical trial and demonstrated significant efficacy in reducing chronic fatigue in MS patients. There is no drug specifically approved for the treatment of chronic fatigue in MS patients anywhere in the world.  MCT-175 for the treatment of relapsing-remitting MS. MCT-175, in preclinical development for the treatment of relapsing-remitting MS, targets disease specific autoaggressive T-cells that destroy the myelin sheath of nerve cells. MCT-175 successfully ameliorated the disease in animal models.  MCT-275 for the treatment of type-1 diabetes. MCT-275, in preclinical development, targets disease-specific autoaggressive T-cells that destroy insulin producing cells in the pancreas. MCT-275 completely reversed the type-1 diabetic phenotype and prolonged life in animal models.  MCT-465 in an adjuvant therapy for the treatment of virus infection and cancer. MCT-465 in preclinical studies successfully reduced pulmonary influenza virus levels 1,000-fold in animal models, and has demonstrated effectiveness in reducing virus levels of HIV and HCV in animal models. MCT-465 in preclinical studies successfully eliminated certain types of tumors in animal models.  The Company also holds unique cell-based technology for use in drug discovery screening applications, and is a leading producer of the cell lines needed by the biotechnology industry to develop new drugs and therapeutics. For more information about MultiCell Technologies, please visit http://www.multicelltech.com.  Contact:  MultiCell Technologies, Inc.  Dr. Stephen Chang, CEO  619-743-3806  MCETInvestor@MultiCelltech.com Source: MultiCell Technologies, Inc.   We Value Your Feedback   Got comments, questions or suggestions? Send 'em on over: Editor@smallcapnetwork.com If you wish to send a written request or inquiry, please send it to our physical address: TGR Group, LLC 4653 Carmel Mtn Rd Suite 308 #402 San Diego, CA 92130 Subscribe Information is power and timely information is profitable. Become informed and profit from SmallCapDigest Profiles and Trading Alerts by becoming a Preferred Member today. There is no cost associated with your email subscription. Add your email address below and make sure to check your email inbox and confirm your opt-in request to start receiving the SmallCapDigest Email Newsletter on a regular basis. To ensure newsletter delivery, you can add any additional email addresses you may have to the SmallCapDigest Member List. Receiving the SmallCapDigest Newsletter in multiple locations is the best way of making sure you don't miss the next investing or trading opportunity! For web based email addresses, the SmallCapDigest recommends @yahoo.com or @aol.com for timely and reliable email newsletter delivery. Subscribe Here Note: Your email address will be kept strictly confidential, and will not be shared with any other entity for any purpose at any time. If you no longer wish to receive the SmallCapDigest, simply follow the instructions located at the bottom of every SmallCapDigest Newsletter Edition. Unsubscribe Here D I S C L A I M E R: The Small Cap Digest, the Small Cap Network, its website and email newsletter (hereafter, cumulatively referred to as "SCD") , is an independent electronic publication committed to providing its readers with factual information on select publicly traded companies. SCD is owned and operated by TGR Group, LLC ("TGR"). TGR is not a registered investment advisor or broker-dealer. All companies are chosen on the basis of certain financial analysis and other pertinent criteria with a view toward maximizing the upside potential for investors while minimizing the downside risk, whenever possible.  Moreover, as detailed below, TGR accepts compensation from third party consultants and/or companies, which it features in the publication and circulation of SCD. To the degrees enumerated herein, SCD should not be regarded as an independent publication.  Click Here or go to http://access.smallcapnetwork.com/compensation_disclosure.html to view our compensation on every company we have ever covered, or visit the following web address: http://www.smallnetwork.net/profile_disclosure.html for our full profiles and http://access.smallcapnetwork.com/short_term_alerts.html for Trading Alerts.  TGR Group LLC has been paid a fee of $15,000 by MultiCell Technologies for coverage of the company. In addition, TGR Group LLC has been pledged 100,000 warrants with an exercise price of $.60, convertible into restricted shares of Multicell, and 100,000 warrants with an exercise price of $.40, convertible into free trading shares of Mutlicell by Trilogy Capital Partners for coverage of the company. From time to time TGR sells shares received as compensation for coverage of client companies. Shares received are sold in the open market. Since the shares are received as compensation for services as previously disclosed, and not for investment purposes, TGR does not view the sale of the shares as contradictory to any opinions delivered in the content. This should be viewed as a conflict of interest by shareholders or prospective shareholders of the client companies.  TGR, its Members and Members' families, are forbidden by company policy to own, buy, sell or otherwise trade stock for their own benefit in the companies who appear in the publication unless specifically disclosed.  All statements and expressions are the sole opinions of TGR and are subject to change without notice. A profile, description, or other mention of a company within SCD is neither an offer nor solicitation to buy or sell any securities mentioned. While we believe all sources of information to be factual and reliable, in no way do we represent or guarantee the accuracy thereof, nor the statements made herein.  THE READER SHOULD VERIFY ALL CLAIMS AND DO THEIR OWN DUE DILIGENCE BEFORE INVESTING IN ANY SECURITIES MENTIONED. INVESTING IN SECURITIES IS SPECULATIVE AND CARRIES A HIGH DEGREE OF RISK. THE INFORMATION FOUND IN THIS PROFILE IS PROTECTED BY THE COPYRIGHT LAWS OF THE UNITED STATES AND MAY NOT BE COPIED, OR REPRODUCED IN ANY WAY WITHOUT THE EXPRESSED, WRITTEN CONSENT OF TGR.  We encourage our readers to invest carefully and read the investor information available at the web sites of the Securities and Exchange Commission ("SEC") at http://www.sec.gov and/or the National Association of Securities Dealers ("NASD") at http://www.nasd.com. We also strongly recommend that you read the SEC advisory to investors concerning Internet Stock Fraud, which can be found at http://www.sec.gov/consumer/cyberfr.htm. Readers can review all public filings by companies at the SEC's EDGAR page. The NASD has published information on how to invest carefully at its web site.